Dr. Lawrence joined the company in 2015. He has twenty years of experience in the pharma/biotech and diagnostics industry in Clinical Development, Translational Medicine, and Medical Affairs at Eli Lilly, BD, Osiris Therapeutics, and Ipsen, where he played key roles in the development of small molecules, biologics, cellular therapy products, and innovative diagnostics. Before joining industry, he held academic research and clinical roles with increasing responsibility at the NIH, Medical College of Virginia, and Case Western Reserve University where he was Associate Professor of Pathology and Director of Hematology and Hematopathology. He obtained his BS and MD degrees from Northwestern University, and trained in anatomic and clinical pathology, hematopathology, and clinical hematology at Northwestern University, Medical College of Virginia, and NIH; he is board certified in anatomic and clinical pathology and hematology. His research interests have been predominantly in hemostasis and thrombosis and platelet physiology, oncology, companion diagnostics, and early drug development, and he is widely published in both basic laboratory and clinical research.
Chief Medical Officer